03:18:53 EDT Tue 19 Mar 2024
Enter Symbol
or Name
USA
CA



ImmunoVaccine Inc
Symbol IMV
Shares Issued 137,130,713
Close 2018-04-24 C$ 1.80
Market Cap C$ 246,835,283
Recent Sedar Documents

ImmunoVaccine, Incyte add phase 2 to combination study

2018-04-24 08:20 ET - News Release

Ms. Patti Bank reports

IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER

ImmunoVaccine Inc. has entered into an agreement with Incyte Corp. to expand their continuing clinical trial collaboration. The companies plan to add a phase 2 component to their continuing phase 1b combination study evaluating the safety and efficacy of ImmunoVaccine's lead candidate, DXP-Survivac, in combination with Incyte's IDO1 enzyme inhibitor epacadostat and low dose cyclophosphamide in advanced ovarian cancer patients.

The phase 2 component will be a randomized, open label, efficacy study that will include up to 32 additional evaluable subjects. It will evaluate DPX-Survivac and low dose cyclophosphamide with, or without, epacadostat in patients with advanced recurrent ovarian cancer. In accordance with regulatory guidelines for combination trials, the goal of this portion of the program is to evaluate the clinical contribution of each investigational drug in the combination regimen.

"We were encouraged by the top-line data we shared last December from the first dosing cohort of our trial, especially in this hard-to-treat population of ovarian cancer patients," said Frederic Ors, chief executive officer at ImmunoVaccine. "We believe that these results further support the hypothesis that the unique mechanism of action underscoring our T-cell activation technology can trigger tumour regressions, even in patients who typically don't respond well to current monotherapies. We are pleased to expand our collaboration with Incyte, and build on the initial demonstration of this combination in ovarian cancer."

The phase 2 arm of the study will be conducted under an amendment to the existing collaboration, in which ImmunoVaccine and Incyte are co-financing the trial.

ImmunoVaccine and Incyte previously reported positive top-line data from the first dosing cohort of the phase 1b portion of the study. Those results showed that the combination of 100 milligrams of epacadostat, in combination with DPX-Survivac and low dose cyclophosphamide, showed a 70-per-cent disease control rate -- including 30 per cent of patients (three out of 10) experiencing partial responses in tumour regression -- and demonstrated a tolerable safety profile. ImmunoVaccine expects to provide a clinical update on the phase 1b program in the first half of 2018.

About DPX-Survivac

DPX-Survivac consists of survivin-based peptide antigens formulated in ImmunoVaccine's proprietary immune-activating delivery technology. DPX-Survivac is thought to work by eliciting a cytotoxic T-cell immune response against cells presenting survivin peptides. Survivin, recognized by the National Cancer Institute (NCI) as a promising tumour-associated antigen, is broadly overexpressed in most cancer types, and plays an essential role in antagonizing cell death, supporting tumour-associated angiogenesis, and promoting resistance to anti-cancer therapies. ImmunoVaccine has identified over 15 cancer indications in which the overexpression of survivin can be targeted by DPX-Survivac. DPX-Survivac received fast-track designation from the U.S. Food and Drug Administration (FDA) as maintenance therapy in advanced ovarian cancer, as well as orphan drug designation status from the U.S. FDA and the European Medicines Agency (EMA) in the ovarian cancer indication.

About ImmunoVaccine Inc.

ImmunoVaccine is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. ImmunoVaccine develops T-cell-activating cancer immunotherapies based on the company's proprietary drug delivery platform. This patented technology provides controlled and prolonged exposure to a broad range of immunogenic stimuli. ImmunoVaccine has advanced two T-cell-activating therapies for cancer through phase 1 human clinical trials and is currently conducting a phase 1b study with Incyte Corp. assessing its lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.